Population: Elderly (≥65 years)

Ortiz

Spain
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • People at high risk of STIs
  • Men who have sex with men
  • Hospital
  • Outpatient clinic
  • Infectious diseases unit
  • Monkeypox virus
  • Mpox

Peghetti

Italy
|
2021-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post COVID-19 condition
  • Non pharmacological intervention
  • Rehabilitation

PHOSP-COVID

United Kingdom
|
2020
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post COVID-19 condition

Platinium

United Kingdom
|
2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Monkeypox virus
  • Mpox
  • Pharmacological intervention
  • Antivirals
  • Tecovirimat

LUNGTERMcov

Switzerland
|
2021-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • Intensive care unit
  • SARS-CoV-2
  • Post COVID-19 condition

Mazzitelli

Italy
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Molnupiravir

Mazzitelli 2

Italy
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Remdesivir

Mertens

Germany
|
2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition

HeijenbrokKal

The Netherlands
|
2020
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post COVID-19 condition

IAMPOCO

Germany
|
2023-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post COVID-19 condition
  • Non pharmacological intervention
  • Immunoadsorption

InvidiCO

Germany
|
2024-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post COVID-19 condition
  • Non pharmacological intervention
  • Rehabilitation
  • Vimida

Jacobi

Germany
|
2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition
  • Non pharmacological intervention
  • Rehabilitation